Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome
- PMID: 33484384
- DOI: 10.1007/s10792-021-01708-1
Topical cyclosporine a (0.05%) treatment in dry eye patients: a comparison study of Sjogren's syndrome versus non-Sjogren's syndrome
Abstract
Purpose: To evaluate the clinical effect of topical cyclosporine A (CsA) (0.05%) on dry eye patients with Sjogren's syndrome (SS) and non-Sjogren's syndrome (NSS).
Method: This retrospective comparative study includes the dry eye (DE) patients who were treated with topical CsA. DE patients were divided into two groups as follows: DE with Sjogren's syndrome (DE-SS) and DE with Non-Sjogren's syndrome (DE-NSS). Dry eye parameters were recorded at baseline and each visit.
Results: Schirmer's test 1 scores were 2.7 ± 0.5 mm at baseline and 3.5 ± 0.7 mm at 12th month in DE-SS, 2.9 ± 0.7 mm at baseline and 9.5 ± 0.7 mm in DE-NSS groups at 12th month. Mean ST score was higher in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (both p = 0.001). Tear break-up time score showed a significant improvement in DE-NSS group, and it was lower in DE-NSS group than DE-SS group group at sixth and 12th months of the treatment (p = 0.044 and 0.027, respectively). Mean OSDI score was lower in DE-NSS group than DE-SS group at sixth and 12th months of the treatment (p = 0.030 and 0.032, respectively).
Conclusion: Topical CsA seems to be more effective in the treatment of the DE-NSS.
Keywords: Cyclosporine; Dry eye; Non-sjogren’s syndrome; Sjogren’s syndrome.
Similar articles
-
Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren's syndrome.BMC Ophthalmol. 2025 Jul 1;25(1):369. doi: 10.1186/s12886-025-04173-x. BMC Ophthalmol. 2025. PMID: 40597071 Free PMC article.
-
Efficacy of Switching from Cyclosporine A 0.05% Anionic Emulsion to Cyclosporine A 0.1% Cationic Emulsion in Patients with Dry Eye Associated with Sjögren's Syndrome.J Ocul Pharmacol Ther. 2021 Oct;37(8):472-478. doi: 10.1089/jop.2020.0146. Epub 2021 Aug 27. J Ocul Pharmacol Ther. 2021. PMID: 34449255
-
Evaluation of the Efficacy and Safety of Topical 0.05% Cyclosporine Eye Drops (II) in the Treatment of Dry Eye Associated with Primary Sjögren's Syndrome.Ocul Immunol Inflamm. 2023 Oct;31(8):1662-1668. doi: 10.1080/09273948.2022.2094812. Epub 2022 Aug 1. Ocul Immunol Inflamm. 2023. PMID: 35914303 Clinical Trial.
-
Sjögren's Syndrome, Non-Sjögren's Syndrome, and Graft-Versus-Host Disease Related Dry Eye.Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES71-DES79. doi: 10.1167/iovs.17-23750. Invest Ophthalmol Vis Sci. 2018. PMID: 30481809 Review.
-
Dry eye in Sjögren's syndrome - characteristics and therapy.Eur J Ophthalmol. 2022 Nov;32(6):3174-3184. doi: 10.1177/11206721221091375. Epub 2022 Mar 30. Eur J Ophthalmol. 2022. PMID: 35354331 Review.
Cited by
-
Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine.Front Med (Lausanne). 2022 Jan 17;8:815075. doi: 10.3389/fmed.2021.815075. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35111787 Free PMC article. Review.
-
Comparison of effects of cyclosporine 0.05% and 0.1% in dry eye with Sjögren's syndrome.BMC Ophthalmol. 2025 Jul 1;25(1):369. doi: 10.1186/s12886-025-04173-x. BMC Ophthalmol. 2025. PMID: 40597071 Free PMC article.
-
OC-01 (Varenicline Solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2.Clin Ophthalmol. 2023 Mar 3;17:725-734. doi: 10.2147/OPTH.S403953. eCollection 2023. Clin Ophthalmol. 2023. PMID: 36895950 Free PMC article.
-
Topical cyclosporine A in the management of dry eye disease in Sjögren's syndrome.Reumatologia. 2024;62(6):395-397. doi: 10.5114/reum/197334. Epub 2024 Dec 19. Reumatologia. 2024. PMID: 39866306 Free PMC article. No abstract available.
-
Role of topical and systemic immunosuppression in aqueous-deficient dry eye disease.Indian J Ophthalmol. 2023 Apr;71(4):1176-1189. doi: 10.4103/IJO.IJO_2818_22. Indian J Ophthalmol. 2023. PMID: 37026249 Free PMC article. Review.
References
-
- (2007) The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf 5(2):75–92. https://doi.org/10.1016/s1542-0124(12)70081-2
-
- Bron AJ, de Paiva CS, Chauhan SK et al (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15(3):438–510 - DOI
-
- Hikichi T, Yoshida A, Tsubota K (1993) Lymphocytic infiltration of the conjunctiva and the salivary gland in Sjogren’s syndrome. Arch Ophthalmol 111(1):21–22 - PubMed
-
- Lee SY, Han SJ, Nam SM et al (2013) Analysis of tear cytokines and clinical correlations in Sjogren syndrome dry eye patients and non-Sjogren syndrome dry eye patients. Am J Ophthalmol 156(2):247–253 - DOI
-
- Liu R, Gao C, Chen H, Li Y, Jin Y, Qi H (2017) Analysis of Th17-associated cytokines and clinical correlations in patients with dry eye disease. PLoS ONE 12(4):e0173301 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical